Patents by Inventor Kenneth M. Boy

Kenneth M. Boy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS
    Publication number: 20240218022
    Abstract: This invention relates to novel anti-VISTA macrocyclic peptides and their related analogs with appended pharmacokinetic-enhancing tails (PKEs) with general structure of formula (I), which can be used as VISTA inhibitors.
    Type: Application
    Filed: November 15, 2023
    Publication date: July 4, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: JENNIFER X. QIAO, YUNHUI ZHANG, KENNETH M. BOY, MICHAEL A. POSS
  • Immunomodulators
    Patent number: 11952434
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • IMMUNOMODULATORS
    Publication number: 20230101323
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 30, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
  • Immunomodulators
    Patent number: 11358988
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • PET-IMAGING IMMUNOMODULATORS
    Publication number: 20210386876
    Abstract: The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
    Type: Application
    Filed: August 26, 2021
    Publication date: December 16, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: David J. DONNELLY, Kenneth M. BOY, Yunhui ZHANG, Joonyoung KIM, Adrienne PENA
  • PET-imaging immunomodulators
    Patent number: 11103605
    Abstract: The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: August 31, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: David J. Donnelly, Kenneth M. Boy, Yunhui Zhang, Joonyoung Kim, Adrienne Pena
  • IMMUNOMODULATORS
    Publication number: 20200216498
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 11, 2019
    Publication date: July 9, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
  • Immunomodulators
    Patent number: 10633419
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • PET-IMAGING IMMUNOMODULATORS
    Publication number: 20190117801
    Abstract: The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
    Type: Application
    Filed: May 17, 2017
    Publication date: April 25, 2019
    Inventors: David J. Donnelly, Kenneth M. Boy, Yunhui Zhang, Joonyoung KIM, Adrienne Pena
  • IMMUNOMODULATORS
    Publication number: 20180086793
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 29, 2018
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 9879046
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: January 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • Immunomodulators
    Patent number: 9856292
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: January 2, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20170369530
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: August 9, 2017
    Publication date: December 28, 2017
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 9850283
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production
    Patent number: 9833454
    Abstract: The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: December 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Stephen E. Mercer, Richard E. Olson, Xiaoliang Zhou
  • Immunomodulators
    Patent number: 9809625
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: November 7, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Paul Michael Scola
  • DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    Publication number: 20170182050
    Abstract: The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.
    Type: Application
    Filed: April 1, 2015
    Publication date: June 29, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Stephen E. Mercer, Richard E. Olson, Xiaoliang Zhou
  • Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions
    Publication number: 20160340391
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: July 7, 2016
    Publication date: November 24, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • Immunomodulators
    Publication number: 20160272680
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 22, 2016
    Inventors: Kenneth M. Boy, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20160158349
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 28, 2016
    Publication date: June 9, 2016
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola